Neon Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Neon Therapeutics's estimated annual revenue is currently $14.1M per year.
- Neon Therapeutics received $36.0M in venture funding in December 2017.
- Neon Therapeutics's estimated revenue per employee is $881,563
- Neon Therapeutics's total funding is $161M.
- Neon Therapeutics has 16 Employees.
- Neon Therapeutics grew their employee count by 14% last year.
Neon Therapeutics Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Neon Therapeutics?
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. For more information, please visit www.neontherapeutics.com.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Neon Therapeutics News
Global Precision Medicine Market Information, Figures and Analytical Insights By 2028 | Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG,...
Moderna Therapeutics; F. Hoffmann-La Roche Ltd; AstraZeneca plc; Agenus; OSE Immunotherapeutics; Advaxis; Medigene; Neon Therapeutics...
Thinly traded nano cap Neon Therapeutics (NASDAQ:NTGN) is up 14% premarket on average volume in response to a just-published paper in ...
Neon Therapeutics Inc (NTGN) stock has fallen -66.87% over the last 12 months, and the average rating from Wall Street analysts is a Strong ...
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Neon Therapeutics Funding
|2015-10-02||$55.0M||A||Third Rock Ventures||Article|
|2017-01-06||$70.0M||B||Partner Fund Management||Article|